Cogentix Medical, Inc. (“Cogentix”, “Cogentix Medical”, or the “Company”), based in Minnetonka, Minnesota with additional operations in Orangeburg, New York, Westbourough, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company that designs, develops, manufactures and markets innovative proprietary technologies serving the urology, urogynecology/gyn, ENT and GI markets.
The FDA-cleared PrimeSight™ Endoscopy Systems revolutionize the efficiency of quality patient care by combining high-performance endoscopic imaging technology with the EndoSheath® Protective Barrier, a sterile, single-use product with an integrated working channel.
The Urgent® PC Neuromodulation System is an FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB).
In the U.S. and worldwide, the Company also offers Macroplastique® a urethral bulking agent for the treatment of stress urinary incontinence. Outside the U.S., the company markets additional bulking agents: PTQ® for the treatment of fecal incontinence and the VOX® for vocal cord augmentation.
Cogentix is committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put the company’s financial performance into perspective.